Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Existing extended-release options, like weekly formulations of semaglutide and dulaglutide, have reduced injection frequency, and future innovations may include monthly formulations or implantable devices that deliver continuous therapy
Published Patent Application 2004/0208829 discloses an aerosol formulation to be inhaled into a patient's lungs
Compounded GLP-1 medications contain compounded formulations of the active ingredient as brand-name products but aren't the same product, aren't FDA-approved, and should never be represented as equivalent to or interchangeable with FDA-approved medications
What Patients Need to Know Still experimental: Like retatrutide, CagriSema is not yet approved by the FDA
318G1042G1053
Weight gain among patients without diabetes was associated with increased osteoporosis risk in both groups
